
AstraZeneca have revised their findings from the US study AZD1222 of their COVID-19 vaccine, announcing a 76% efficacy against symptoms …

MSD has announced a provisional agreement with the NHS to make KEYTRUDA (pembrolizumab) available for eligible patients with metastatic MSI-H/dMMR …

Both AstraZeneca and J&J face major manufacturing deficiencies for their recombinant vector COVID-19 vaccines, forcing competition over limited production capacity …

The past week has seen plenty of positive COVID-19 news; the Oxford-AstraZeneca vaccine was deemed safe and effective by the …

Roche’s antibody drug combination of casirivimab and imdevimab has shown to reduce hospitalisation or death by 70% in non-hospitalised patients …

Pfizer and Myovant Science’s relugolix treatment to reduce menstrual blood loss in women with uterine fibroids has shown promising results …

New results from Novo Nordisk’s Phase III study on obesity saw clinically relevant weight loss, without weight regain, in people …

Medical imaging company, Guerbet, have announced the success of its Phase III study into the safety and efficacy of Gadopiclenol, …

The FDA have approved Zealand Pharma’s Zegalogue therapy for the treatment of severe hypoglycemia in patients with diabetes.

The Japanese Ministry of Health, Labour, and Welfare (MHLW) have approved Incyte’s Pemazyre (pemigatinib) for the treatment of patients with …

Accord Healthcare has announced the UK launch of a generic thalidomide, which is used in combination with melphalan and prednisone, …

Roche has discontinued dosing in a Phase III trial of its tominersen treatment for Huntington’s disease, following discouraging initial data.

Novartis has today announced positive results from its Phase III VISION study with 177Lu-PSMA-617, seeing significant improvements in overall survival …

eTheRNA immunotherapies, a clinical-stage company, has been awarded a grant of €6.9 million by the European Commission to develop a …

Daiichi Sankyo, a global pharmaceutical company that provides services in 20 countries worldwide, has announced the first vaccinations as part …

The FDA have approved ARCALYST (rilonacept) for the treatment and risk reduction of recurrent pericardis in adults and children over …

Roche’s IMpower010 study, evaluating Tecentriq (atezolizumab) compared with best supportive care, has shown significant improvement in disease-free survival (DFS) in …

Results from the US trial of AstraZeneca’s COVID-19 vaccine (AZD1222) show it is 79% effective at stopping symptomatic COVID-19 disease …

In the last week, a number of new developments have made the news; for COVID-19, the Oxford-AstraZeneca vaccine has been …

The Russian Direct Investment Fund (RDIF) and Stelis Biopharma have today announced a partnership which aims to produce and supply …